IP Library › Granted Patent US 12,484,962
Granted Patent B2
US 12,484,962 · App. 18/879,966 · Granted Dec 2, 2025

Systems and methods of denervation around subclavian arteries

Inventors: Anthony Vincent Caparso (North Ridgeville, OH); Arun Sridhar (Milton Keynes, GB)
Assignee: Artha Partners B.V.
A61B18/1492A61B2018/00345A61B2018/00434A61B2018/00577A61B2018/0212
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,484,962
App. No.
18/879,966
Granted
Dec 2, 2025
Kind
B2
Abstract

A method of treating heart disease in a subject includes percutaneously introducing a catheter into vasculature of the subject. The catheter may include a neuromodulation element. The neuromodulation element may be positioned on an expansion element. The neuromodulation element of the catheter can be positioned in a subclavian artery of the subject. The catheter can be used to electrically stimulate at least one of a dorsal subclavian ansae or a ventral subclavian ansae. The method can include confirming stimulation of the dorsal subclavian ansae and/or the ventral subclavian ansae by monitoring a cardiac parameter. After confirming stimulation of the dorsal subclavian ansae and/or the ventral subclavian ansae, ablation energy can be provided to the dorsal subclavian ansae and/or the ventral subclavian ansae.

Claims (36)

1 . A method of treating heart disease in a subject, the method comprising:

percutaneously introducing a catheter into vasculature of the subject, wherein the catheter comprises a neuromodulation element;

positioning the neuromodulation element in a left subclavian artery of the subject;

electrically stimulating a left dorsal subclavian ansae;

confirming stimulation of the left dorsal subclavian ansae by monitoring a first cardiac parameter;

after confirming stimulation of the left dorsal subclavian ansae, providing ablation energy to the left dorsal subclavian ansae;

electrically stimulating a left ventral subclavian ansae;

confirming stimulation of the left ventral subclavian ansae by monitoring a second cardiac parameter;

after confirming stimulation of the left ventral subclavian ansae, providing ablation energy to the left ventral subclavian ansae;

positioning the neuromodulation element in a right subclavian artery of the subject;

electrically stimulating a right dorsal subclavian ansae;

confirming stimulation of the right dorsal subclavian ansae by monitoring a third cardiac parameter;

after confirming stimulation of the right dorsal subclavian ansae, providing ablation energy to the right dorsal subclavian ansae;

electrically stimulating a right ventral subclavian ansae;

confirming stimulation of the right ventral subclavian ansae by monitoring a fourth cardiac parameter; and

after confirming stimulation of the right ventral subclavian ansae, providing ablation energy to the right ventral subclavian ansae.

2 . The method of claim 1 , wherein the first cardiac parameter is different than at least one of the second cardiac parameter, the third cardiac parameter, or the fourth cardiac parameter.

3 . The method of claim 1 , wherein the first cardiac parameter is the same as at least one of the second cardiac parameter, the third cardiac parameter, or the fourth cardiac parameter.

4 . The method of claim 1 , wherein at least one of the first cardiac parameter, the second cardiac parameter, the third cardiac parameter, or the fourth cardiac parameter comprises at least one of arterial trace blood pressure change, whether AF is induced, whether arrhythmia is induced, whether a change in cardiac cycle length is induced, repeat restitution curve, right atrial ERP, left atrial ERP, dERP, heart rate, IACT, or unipolar electrogram from multipolar catheter under steady state RV pacing or with short DI after steady state RV pacing.

5 . The method of claim 1 , further comprising, after providing ablation energy, restimulating the subclavian ansae and, if a cardiac parameter confirms stimulation, providing further ablation energy to the subclavian ansae.

6 . The method of claim 5 , comprising repeating the restimulating and providing further ablation energy until the cardiac parameter does not confirm stimulation.

7 . The method of claim 1 , wherein the catheter includes an expansion element on which the neuromodulation element is positioned.

8 . A method of treating heart disease in a subject, the method comprising:

percutaneously introducing a catheter into vasculature of the subject, wherein the catheter comprises a neuromodulation element;

positioning the neuromodulation element in a subclavian artery of the subject;

electrically stimulating a dorsal subclavian ansae;

confirming stimulation of the dorsal subclavian ansae by monitoring a first cardiac parameter;

after confirming stimulation of the dorsal subclavian ansae, providing ablation energy to the dorsal subclavian ansae;

electrically stimulating a ventral subclavian ansae;

confirming stimulation of the ventral subclavian ansae by monitoring a second cardiac parameter; and

after confirming stimulation of the ventral subclavian ansae, providing ablation energy to the ventral subclavian ansae.

9 . The method of claim 8 wherein the first cardiac parameter is different than the second cardiac parameter.

10 . The method of claim 8 , wherein the first cardiac parameter is the same as the second cardiac parameter.

11 . The method of claim 8 , wherein at least one of the first cardiac parameter or the second cardiac parameter comprises at least one of arterial trace blood pressure change, whether AF is induced, whether arrhythmia is induced, whether a change in cardiac cycle length is induced, repeat restitution curve, right atrial ERP, left atrial ERP, dERP, heart rate, IACT, or unipolar electrogram from multipolar catheter under steady state RV pacing or with short DI after steady state RV pacing.

12 . The method of claim 8 further comprising, after providing ablation energy, restimulating the subclavian ansae and, if a cardiac parameter confirms stimulation, providing further ablation energy to the subclavian ansae.

13 . The method of claim 12 , comprising repeating the restimulating and providing further ablation energy until the cardiac parameter does not confirm stimulation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2025
From: CAPARSO, ANTHONY VINCENT; SRIDHAR, ARUN
To: ARTHA PARTNERS B.V.
Reel/Frame 069801/0001 →
Continuity (3)
Provisional Application 63430614 · Dec 6, 2022
Provisional Application 63367578 · Jul 1, 2022
Related Publication 20250160940A1 · May 22, 2025
References Cited (63)
US 5203326A · Collins · 1993 [cited by applicant]
US 6164283A · Lesh · 2000 [cited by applicant]
US 6292695B1 · Webster, Jr. et al. · 2001 [cited by applicant]
US 6487446B1 · Hill et al. · 2002 [cited by applicant]
US 6532388B1 · Hill et al. · 2003 [cited by applicant]
US 6564096B2 · Mest · 2003 [cited by applicant]
US 6937896B1 · Kroll · 2005 [cited by applicant]
US 7123961B1 · Kroll et al. · 2006 [cited by applicant]
US 7139607B1 · Shelchuk · 2006 [cited by applicant]
US 7142917B2 · Fukui · 2006 [cited by applicant]
US 7225017B1 · Shelchuk · 2007 [cited by applicant]
US 7245967B1 · Shelchuk · 2007 [cited by applicant]
US 7277761B2 · Shelchuk · 2007 [cited by applicant]
US 7305265B2 · Fukui · 2007 [cited by applicant]
US 8386053B2 · Kornet · 2013 [cited by examiner]
US 9480790B2 · Machado et al. · 2016 [cited by applicant]
US 10172549B2 · Waldhauser et al. · 2019 [cited by applicant]
US 10188343B2 · Goedeke et al. · 2019 [cited by applicant]
US 20030100924A1 · Foreman et al. · 2003 [cited by applicant]
US 20030216792A1 · Levin et al. · 2003 [cited by applicant]
US 20040138713A1 · Stickney et al. · 2004 [cited by applicant]
US 20050149148A1 · King · 2005 [cited by applicant]
US 20050288730A1 · Deem et al. · 2005 [cited by applicant]
US 20070100380A1 · Fukui · 2007 [cited by applicant]
US 20070191895A1 · Foreman et al. · 2007 [cited by applicant]
US 20070299476A1 · Park et al. · 2007 [cited by applicant]
US 20080021503A1 · Whitehurst et al. · 2008 [cited by applicant]
US 20080051839A1 · Libbus et al. · 2008 [cited by applicant]
US 20080119907A1 · Stahmann · 2008 [cited by applicant]
US 20100114254A1 · Kornet · 2010 [cited by applicant]
US 20120071870A1 · Salahieh et al. · 2012 [cited by applicant]
US 20150119790A1 · Moffitt et al. · 2015 [cited by applicant]
US 20160175041A1 · Govari et al. · 2016 [cited by applicant]
US 20160317621A1 · Bright · 2016 [cited by applicant]
US 20190184172A1 · Ardell et al. · 2019 [cited by applicant]
US 20200214635A1 · Dahlen et al. · 2020 [cited by applicant]
US 20210001116A1 · Waldhauser · 2021 [cited by examiner]
US 20210069504A1 · Hunsberger et al. · 2021 [cited by applicant]
US 20210069511A1 · Hunsberger et al. · 2021 [cited by applicant]
US 20210244951A1 · Cha et al. · 2021 [cited by applicant]
US 20210315638A1 · Townley · 2021 [cited by examiner]
EP 3238646A2 · 2017 [cited by applicant]
WO WO2024006466A1 · 2024 [cited by applicant]
WO WO2025144924A1 · 2025 [cited by applicant]
International Search Report and Written Opinion issued in PCT Application No. PCT/US2023/026620, mailed Dec. 7, 2023, in 19 pages. [cited by applicant]
Ardell et al., (2016). Translational neurocardiology: preclinical models and cardioneural integrative aspects. The Journal of physiology, 594(14), 3877-3909. https://doi.org/10.1113/JP271869. [cited by applicant]
Armour (2008). Potential clinical relevance of the ‘little brain’ on the mammalian heart. Experimental physiology, 93(2), 165-176. https://doi.org/10.1113/expphysiol.2007.041178. [cited by applicant]
Beaumont et al. (2013). Network interactions within the canine intrinsic cardiac nervous system:implications for reflex control of regional cardiac function. The Journal of physiology, 591(18), 4515-4533. https://doi.or… [cited by applicant]
Bourke et al. (2010). Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. Circulation, 121(21), 2255-2262. https://doi.or… [cited by applicant]
Buckley et al. (2016). Targeted stellate decentralization: Implications for sympathetic control of ventricular electrophysiology. Heart rhythm, 13(1), 282-288. https://doi.org/10.1016/j.hrthm.2015.08.022. [cited by applicant]
Choi et al. (2010). Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. Circulation, 121(24), 2615-2623. https://doi.org/10.1161/CIRCULATIONAHA. 109.919829. [cited by applicant]
Huang et al. (2020). The presence of ectopic atrial rhythm predicts adverse cardiovascular outcomesin a large hospital-based population. Heart Rhythm, 17(6), 967-974. https://doi.org/10.1016/j.hrthm.2020.01.024. [cited by applicant]
Leftheriotis et al. (2016). Acute effects of unilateral temporary stellate ganglion block on humanatrial electrophysiological properties and atrial fibrillation inducibility. Heart rhythm, 13(11), 2111-2117. https://doi… [cited by applicant]
Mohan et al. (2001). Intermittent hypoxia modulates nNOS expression and heart rate response to sympathetic nerve stimulation. American journal of physiology. Heart and circulatory physiology, 281(1), H132-H138. https://… [cited by applicant]
Pachon et al. (2015). Simplified Method for Vagal Effect Evaluation in Cardiac Ablation and Electrophysiological Procedures. JACC. Clinical electrophysiology, 1(5), 451-460. https://doi.org/10.1016/j.jacep.2015.06.008. [cited by applicant]
Pistoia et al. (2016). The Epidemiology of Atrial Fibrillation and Stroke. Cardiology clinics, 34(2), 255-268. https://doi.org/10.1016/j.ccl.2015.12.002. [cited by applicant]
Priori et al. (2013). HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF,… [cited by applicant]
Rana et al. (2011). Chronic electrical neuronal stimulation increases cardiac parasympathetic tone by eliciting neurotrophic effects. Circulation Research, 108(10), 1209-1219. https://doi.org/10.1161/circresaha.110.2345… [cited by applicant]
Schwartz et al. (2004). Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation, 109(15), 1826-1833. https://doi.org/10.1161/01.CIR.0000125523.14403.1E. [cited by applicant]
Schwartz et al. (1976). Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. The American journal of cardiology, 37(7), 1034-1040. https://doi.org/10.1016/0002-9149(76)90420-3. [cited by applicant]
Vaseghi et al. (2017). Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias. Journal of the American College of Cardiology, 69(25), 3070-3080. https://doi.org/10.1016/j.jacc.2017.04.035. [cited by applicant]
Vaseghi et al. (2014). Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart rhythm, 11(3), 360-366. https://doi.org/10.1016… [cited by applicant]
Wilde et al. (2008). Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. The New England journal of medicine, 358(19), 2024-2029. https://doi.org/10.1056/NEJMoa0708006. [cited by applicant]